Potential future dermatological indications for tacrolimus ointment.
Tacrolimus ointment is a steroid-free topical immunomodulator developed for the treatment of atopic dermatitis, a common, chronic inflammatory skin disease. By inhibiting T-cell activation and cytokine production, topically applied tacrolimus modulates inflammatory responses in the skin. Numerous clinical trials have shown that it is effective and well tolerated for the treatment of atopic dermatitis, its licensed indication. In addition, numerous publications suggest that tacrolimus ointment may provide effective treatment for a variety of other inflammatory skin disorders, many of which are very difficult to manage with standard therapy. This paper reviews currently available evidence regarding the use of tacrolimus ointment in a range of dermatological disorders, including psoriasis, lichen planus, pyoderma gangrenosum, lichen sclerosus, contact dermatitis, leg ulcers in rheumatoid arthritis, steroid-induced rosacea and alopecia areata. It also provides recommendations for future clinical studies with tacrolimus ointment.
Ruzicka
Thomas
T
Department of Dermatology, University of Düsseldorf, Moorenstr 5, 40225 Düsseldorf, Germsny.
Assmann
Till
T
Lebwohl
Mark
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000279:Administration, Cutaneous; D000506:Alopecia Areata / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003877:Dermatitis, Contact / Q000188:drug therapy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy; D008010:Lichen Planus / Q000188:drug therapy; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D012393:Rosacea / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D003879:Dermatologic Agents; D009824:Ointments; D016559:Tacrolimus